Clinical trialPhase 1 / Phase 2Completed
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
- Outcome
- Outcome unknown
- Phase
- Phase 1 / Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 25 March 2015
- Expected end
- 31 December 2020
- Enrollment
- 65 participants
- Sites
- 1
- Primary outcomes
- Number of Adverse Events in Each Cohort With Grade 1 Through 5 Related to Study Drug
- Sponsor
- Nih
- Results posted
- 2020-07-17
- Last update
- 20 April 2021
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try